OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data

Taha A Kass-Hout1, Zhiheng Xu1, Matthew Mohebbi2, Hans Nelsen2, Adam Baker2, Jonathan Levine1, Elaine Johanson1, Roselie A Bright1

ABSTRACT

Objective The objective of openFDA is to facilitate access and use of big important Food and Drug Administration public datasets by developers, researchers, and the public through harmonization of data across disparate FDA datasets provided via application programming interfaces (APIs).

Materials and Methods Using cutting-edge technologies deployed on FDA’s new public cloud computing infrastructure, openFDA provides open data for easier, faster (over 300 requests per second per process), and better access to FDA datasets; open source code and documentation shared on GitHub for open community contributions of examples, apps and ideas; and infrastructure that can be adopted for other public health big data challenges.

Results Since its launch on June 2, 2014, openFDA has developed four APIs for drug and device adverse events, recall information for all FDA-regulated products, and drug labeling. There have been more than 20 million API calls (more than half from outside the United States), 6000 registered users, 20,000 connected Internet Protocol addresses, and dozens of new software (mobile or web) apps developed. A case study demonstrates a use of openFDA data to understand an apparent association of a drug with an adverse event.

Conclusion With easier and faster access to these datasets, consumers worldwide can learn more about FDA-regulated products.

Keywords: openFDA, drug safety, adverse event, API, application programming interface, open data, open source

BACKGROUND AND SIGNIFICANCE

In the United States, Food and Drug Administration (FDA)-regulated products account for about 25 cents of every dollar spent by American consumers each year—products that touch the lives of every American every day.1 Americans rely on the FDA to keep their food, medical products, and other FDA-regulated products safe, and where applicable, effective. FDA’s major activities regarding marketed products are to:

- Require firms that manufacture or distribute FDA-regulated products to register with FDA, list the products, and provide the labeling on those products.
- Review reports of adverse events, which may include patient or user harm, use error, and/or a quality problem with the product, to monitor marketed products. FDA accepts all voluntary reports and has issued reporting requirements that vary with the particular type of product.
- Inspect firms and/or products, either routinely or as part of an investigation prompted by an adverse event report or other concern.
- Monitor product recalls, which most often are manufacturer initiated.

To address these difficulties FDA launched the openFDA project in March 2013. The first priority were databases with a combination of high general consumer interest, low accessibility on www.fda.gov, and high interest on the part of the FDA organization that stewards the database.

Correspondence to Zhiheng Xu, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA; zhiheng.xu@fda.hhs.gov; Tel: 301-796-6094; Fax: 301-847-8123
© The Author 2015. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com For numbered affiliations see end of article.
The architecture and technology were chosen to make openFDA scalable, quickly responsive, and transparent. The data are on the cloud that matures easily accessible by application developers, researchers, and able quickly responsive; transferable to new technologies as they become available. The design of the open.fda.gov website draws on best practices in agile development, intuitive user experience, and data visualization, aiming to provide one unified, simple presentation to users. The site is characterized by a combination of interactive programmer-friendly queries, visualizations and examples that help explain the nature of the data and how to use JSON URL query command syntax. Plain language is used throughout.

**RESULTS**

**Use of openFDA in Applications**

Since the launch of openFDA, a growing community on StackExchange has been engaged in discovering novel ways to use, integrate, and analyze the openFDA data. By mid-July 2015, there have been more than 20 million API calls (more than half of which were generated outside the United States), more than 6000 registered API users, and more than 1800 Twitter followers. Twitter has been used to broadcast openFDA news and followers’ feedback and announcements. For example, some followers have shared their experiences of using openFDA to study gender differences in reported drug side effects and to cross reference openFDA data with other databases.

As a result of the US General Services Administration’s Request for Quotes on June 17th that requires responders to build working prototype apps that use openFDA and post them in GitHub or BitBucket, dozens of prototypes have been posted on GitHub. Apps have been developed that allow a consumer who experiences an adverse event to determine whether there is a report of anyone else having a similar experience after taking the same drug. An interactive dashboard display of drug reports was published as a “hobby.” More advanced statistics are available on a family of public sites used in the following case study.

**Case Study: The Causal Relationship between Aspirin and Flushing**

This case illustrates some of the professional pharmacovigilance processes for assessing an apparent association between a drug and a particular adverse event in a collection of drug adverse event reports summarized in a public FDA guidance document. In the past, triggers of increased adverse event reporting to FDA have included news announcements. For example, some followers have shared their experiences of using openFDA to study gender differences in reported drug side effects and to cross reference openFDA data with other databases.

Among the many other issues with drawing causality conclusions from the reports are limited knowledge of the relative extent of use of the drugs involved, and various other alternative explanations for the apparent association. Aspirin is one of the most common drugs listed in openFDA drug adverse event reports (4.2% of all reports). A natural question is what types of adverse events have been reported for aspirin? Or, this could be rephrased as, what types of adverse events were more often reported in the same reports as aspirin, compared to reports that do not mention aspirin? A proportional reporting rate (PRR), a commonly used statistic for this question, of 2 indicates that the proportion of reports for the drug-event combination is twice the proportion of the event in the overall database. Using an interactive program designed to look at openFDA drug reports data, we can quickly look at the most common events for aspirin (Table 1). Further details of the steps used in this case can be found at https://open.fda.gov/updates/.
“Flushing” is the most common event, with 6% (10,071/169,838) of all reports mentioning aspirin also mentioning flushing. Furthermore, the PRR indicates that a report containing aspirin is more than seven times as likely to include flushing as a report that does not contain aspirin. Labeling for aspirin does not include flushing in the list of adverse events. Before concluding that aspirin causes flushing, one must rule out noncausal explanations of the association, including, but not limited to: 1) the association was a chance occurrence, 2) an extraneous event resulted in the apparent association, 3) the event was related to the underlying condition that prompted the medication use, and 4) other medications are responsible for the relationship.

Explanations 1) and 2) can be investigated using a dynamic PRR graph (Figure 1).

In Figure 1 we see that before 2009 there was little or no statistical association between aspirin and flushing, with the PRR values only slightly above 1, and the 95% confidence intervals often including 1. After 2008 we see the PRR rapidly increase to 4, and then increase further to between 7 and 9. The confidence intervals for post 2008 data all exclude 1, so these are unlikely to be a chance association. The dramatic increase after 2008 suggests an explanatory event in 2008.

In addition, other medication(s) could explain the relationship. Each report allows mentions of multiple drugs and multiple events. Table 2 shows the most common drugs mentioned in reports that also mention aspirin and flushing.

Using openFDA drug labeling, we found that the drugs in Table 2 that list “flushing” are “niacin,” “niacin and simvastatin,” and “lisinopril.” The combination of niacin with simvastatin was first approved as Simcor, February 19, 2008, just before the rise in reports noted in Figure 1. Niacin was reported to reduce the risk of myocardial infarction and stroke in 1975, and to reduce atherosclerosis beginning in 1987. Consensus guidelines for niacin therapy were published in 2012 and 2013. Lisinopril was approved in 1988. We then tested whether these three drugs explain all of the apparent association between aspirin and flushing. Looking at aspirin reports that do not mention niacin or lisinopril results in the complete absence of flushing from the list of associated adverse events.

In summary, we have demonstrated that a drug-event association is unlikely to be causal. Research beyond the reporting data is usually essential to fully understand the relationship between drug-event pairs. For example, Cefali et al. found that aspirin is a good way to treat flushing. Our case may be a drug (niacin) causing the event (flushing), and an event (flushing) leading to use of the drug (aspirin).

**DISCUSSION**

The openFDA initiative makes it possible for technology specialists to effectively, automatically, and quickly search, query, or pull massive amounts of public information directly from FDA datasets via URL queries to APIs. As the case study illustrated, openFDA allows users to quickly conduct a variety of analyses to explore the nature of posted data.
As we focus on making existing public datasets accessible in new ways, it is important to note that only data that has already been cleared for public use is considered for openFDA. This is the practical reason that narrative descriptions of drug adverse event reports are not in the public datasets. The absence of the narratives from the drug reports is enough to prevent drawing any valid conclusions from solely the openFDA drug report data.

For the first time, the recalls data are more readily searchable and the drug labeling data are searchable on any of the standard labeling fields.

CONCLUSION
OpenFDA brings a new model of big data search and analytics across disparate and complex sources by simplifying dataset structures. With easier and better access, users can learn more about FDA-regulated products, as shown in the case study of aspirin and flushing. A new open community shares code, documentation, examples, apps, and ideas related to openFDA. As the president’s executive order stated, “openness in government . . . promotes the delivery of efficient and effective services to the public.” We invite use of openFDA for entrepreneurship, innovation, and scientific discovery.

FUNDING
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

COMPETING INTERESTS
The authors have no competing interests to declare.

CONTRIBUTORS
Dr T.A.K.-H. spearheaded the conception and design of the openFDA project. He made significant contributions to the conceptualization of the article and review and synthesis of the literature. Dr Z.X. wrote the initial draft of the manuscript and conducted data analysis. M.M., H.N., A.B., and Russell Power developed openFDA API. Dr J.L. and E.J. conducted case study analysis. Dr R.A.B. contributed content, critical review, and revision of the manuscript.

ACKNOWLEDGEMENTS
The authors wish to acknowledge the ongoing support of the core openFDA team of FDA employees (Steven Hubbard and Kelemework Yimam) and the wider past and current openFDA team (Sharon Campbell, Sean Herron, and Joe Neubauer). The openFDA team has relied heavily on participation by data owners in the FDA programs (Sandra Abbott, Steven Anderson, Yulia Borodina, Erin Brandt, Eric Brodsky, Margarita Brown, Isaac Chang, Lisa Creason, Suranjani De, Ann Ferriter, David Gartner, Marni Hall, David Heller, Randy Levin, Canida Lyle, Elias Mallis, Stanley Mistleton, Jonathan Montgomery, Franklin Ohaegbu, Glenn Peterson, John Quinn, Greg Parker, Lilliam Rosario, Nancy Sager, Jeff Shuren, Ella Smith, Lonnie Smith, Daniel St. Laurent, Kevin Starry, Katherine Vierk, and Linda Walter-Grimm); they provided crucial help to prioritize which datasets to make available, get the right data, ensure data quality, and properly document the data. The authors also appreciate support from Ricky Cokely, Mildred Cooper, Andrea Fischer, Jenny Gentry, Amber Griffin, Margaret Hamburg, Janet Woodcock, Walter Harris, Joshua Lehman, Angelique Hebert, Milan Kubic, Alan McClelland, Rosie Owens, Jeff Ventura, Bradford Wintemute, Sean Wybenga, and Carolyn Yancey.

REFERENCES
AUTHOR AFFILIATIONS

1. U.S. Food and Drug Administration, Silver Spring, MD, USA
2. Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA


